Skip to content

Using Clinical Prediction Models to Improve Treatment for Patients With Chronic Obstructive Pulmonary Disease (COPD)

IMplementing Predictive Analytics Towards Efficient COPD Treatments (IMPACT) Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05309356
Enrollment
1130
Registered
2022-04-04
Start date
2023-03-21
Completion date
2025-07-31
Last updated
2023-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

Precision medicine, Clinical prediction models, Medication adherence, Prescription appropriateness, Decision aid

Brief summary

Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease of the lungs that affects more than 2.5 million Canadians. Patients with COPD experience episodes of lung attacks (or exacerbations). During these attacks, patients experience an intense increase in symptoms, such as breathlessness and cough. It is challenging to decide which patients should be put on treatments that would reduce the risk of such lung attacks. The digitization of health records in many clinics and hospitals means complex risk prediction algorithms can be used to predict the risk of lung attacks to enable personalized care. In this study, our team will implement a risk prediction tool (called ACCEPT) into the electronic health records in two teaching hospitals in Vancouver, British Columbia (BC), Canada. A clinical study will be conducted to evaluate if the use of this tool results in patients with COPD receiving better care with better outcomes, and if they are more satisfied with the care they are receiving.

Detailed description

COPD is a heterogenous and progressive disease of the airways that affects millions of people worldwide. However, current treatment guidelines fail to provide personalised, patient-centered disease management. In contrast, precision medicine emphasizes the tailoring of disease management to patient characteristics and values to optimize patient care and outcomes. Clinical prediction models (CPMs) are major enablers of precision medicine, and facilitate targeted therapies to patients who will benefit the most from them. The investigators developed a CPM called ACCEPT that improves risk stratification for COPD patients by predicting the risk of exacerbation at an individual level and thereby enabling personalized, preventive disease management. Using a stepped wedged cluster randomized controlled trial (RCT), the investigators aim to evaluate the impact of integrating ACCEPT into routine COPD care at two outpatient respiratory clinics in Vancouver, British Columbia, Canada. The 'stepped wedged' RCT has a cross-over design, with treatment assignment done in a uni-directional, staggered format that will provide opportunities to control for time trend. The total duration of the study is 30 months. There will be a one-month phase in period with patient recruitment and data collection starting on month two. The last physician assignment will occur in month 18, and patient recruitment will continue until month 24. Follow-up data will be collected until month 30 to ensure six months of follow-up data for all patients. Primary and secondary outcomes will be analysed using generalized estimating equations to account for possible clustering of endpoints (multiple visits for each physician). Further, following the intention to treat principle, clusters (physicians) will be analyzed according to their randomized crossover time irrespective of whether crossover was achieved at the desired time.

Interventions

OTHERACCEPT Decision Intervention

The intervention consists of the CPM (ACCEPT) that is integrated with a decision aid, together called the ACCEPT Decision Intervention (ADI). The ADI will provide physicians with a quantification of the exacerbation risk for each patient and the corresponding treatment recommendation, as well as information about the benefits and risks of different inhaled therapies to discuss with the patients. The intervention also includes a 1-page take-home pamphlet on evidence-based risk behaviour factor modification for COPD, tailored to the treatment recommendation.

OTHERComparator

The patient will receive the physician-recommended treatment for COPD (usual care). All physicians will be provided refresher training on the Canadian Thoracic Society COPD guidelines during the phase in period (month 1).

Sponsors

Providence Health & Services
CollaboratorOTHER
Vancouver Coastal Health
CollaboratorOTHER_GOV
University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

The investigators will conduct a prospective, pragmatic two-year stepped-wedged cluster RCT to evaluate the impact of ACCEPT on the process of care, patient-reported, and clinical outcomes. The trial was designed based on 24 participating physicians, comprising the study clusters. All physicians will be assigned to the comparator arm (usual care) at the beginning of the study. After 6 months, under a sequential rollout, two randomly selected physicians will be reassigned to the intervention arm (ACCEPT) every month.

Eligibility

Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Are a legal Canadian resident * Aged 35 years and older * Can speak English * Have a diagnosis of COPD

Exclusion criteria

• Are under 35 years of age

Design outcomes

Primary

MeasureTime frameDescription
Prescription appropriatenessCross-sectional: data collected during each patients initial study visit for the duration of the trial (24 months)Binary variable indicating the concordance between the physician- and ACCEPT-based treatment recommendations (0: discordant prescription, 1: concordant prescription). We will compare the percentage of prescription appropriateness between the two study arms. The prescription recommended by the physician during the clinical encounter will be recorded. After the encounter, a research coordinator will interview the patient, use ACCEPT to produce the ACCEPT-based optimal treatment for the patient. The physician prescription will be considered concordant if it is the same as the prescription based on the ACCEPT recommendation (or if ACCEPT suggests more than one eligible prescription, the physician prescription is one of them), otherwise it will be considered discordant.

Secondary

MeasureTime frameDescription
Medication adherence1 year before and 1 year after initial study visit (day 1).Medication adherence will be measured by the Medication Possession Ratio, defined as the ratio of the total days' supply dispensed to the total days' supply prescribed during the study period. This outcome will be assessed by linking patient data to BC's administrative health databases using each individual's unique Personal Health Number.
Rate of moderate or severe exacerbations1 year before and 1 year after initial study visit.This outcome will be assessed by linking patient data to BC's administrative health databases using each individual's unique Personal Health Number. Moderate exacerbations will be defined any outpatient physician visit for COPD followed by filling prescriptions for antibiotic or oral corticosteroids. Severe exacerbations will be define as hospital admission with the main discharge code of COPD.
Self-reported medication adherence and beliefsBMQ-COPD will be administered at baseline (study visit 1, day 1), month 3, and month 6COPD-specific Beliefs about Medicines Questionnaire (BMQ)
Impact of COPD on patient's daily lifeCAT will be administered at baseline (study visit 1, day 1), month 3, and month 6Measured by the COPD Assessment Test (CAT)
COPD patient's Quality of LifeEQ5D will be administered at baseline (study visit 1, day 1), month 3, and month 6Measured by the EuroQoL 5-dimension (EQ5D) questionnaire

Countries

Canada

Contacts

Primary ContactMohsen Sadatsafavi, MD, PhD
mohsen.sadatsafavi@ubc.ca(604) 827-3020
Backup ContactDon Sin, MD, MPH
Don.Sin@hli.ubc.ca(604) 806-8395

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026